Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 6/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5652129 | 0.88 | CA2 (0.53) | KCNH2HRH3CA2CA12CA1 | |
| SCHEMBL12855839 | 0.87 | KCNH2 (0.59) | KCNH2HRH3CA2ALDH1A1LMNA | |
| SCHEMBL1938557 | 0.86 | KCNH2 (0.58) | KCNH2HRH3ALDH1A1LMNAHPGD | |
| SCHEMBL1938454 | 0.86 | KCNH2 (0.58) | KCNH2HRH3ALDH1A1LMNAHPGD | |
| SCHEMBL12863268 | 0.84 | KCNH2 (0.55) | KCNH2HRH3CA2ALDH1A1LMNA | |
| SCHEMBL12855853 | 0.84 | CA2 (0.50) | KCNH2CA2CA12CA1CA4 | |
| SCHEMBL1128229 | 0.83 | KCNH2 (0.56) | KCNH2HRH3CA2CA1ALDH1A1 | |
| SCHEMBL1128049 | 0.82 | KCNH2 (0.54) | KCNH2HRH3ALDH1A1LMNAHPGD | |
| SCHEMBL12855835 | 0.82 | KCNH2 (0.54) | KCNH2HRH3ALDH1A1LMNAHPGD | |
| SCHEMBL13659532 | 0.82 | KCNH2 (0.51) | KCNH2HRH3ALDH1A1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110040105-A1 | PROCESSES USEFUL FOR THE SYNTHESIS OF (R)-1--2-METHYL-PYRROLIDINE | ARENA PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110040105-A1 | PROCESSES USEFUL FOR THE SYNTHESIS OF (R)-1--2-METHYL-PYRROLIDINE | ARENA PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110040105-A1 | PROCESSES USEFUL FOR THE SYNTHESIS OF (R)-1--2-METHYL-PYRROLIDINE | ARENA PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| EP-2282992-A1 | PROCESSES USEFUL FOR THE SYNTHESIS OF (R)-1-{2-Ý4'-(3-METHOXYPROPANE-1-SULFONYL)-BIPHENYL-4-YL¨-ETHYL}-2-METHYL-PYRROLIDINE | Arena Pharmaceuticals, Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| US-20100292288-A1 | CRYSTALLINE FORMS OF (R)-1-{2-[4`- (3-METHOXY-PROPANE-1- SULFONYL)-BIPHENYL-4-YL]-ETHYL}-2-METHYL-PYRROLIDINE, AND COMPOSITIONS, AND METHODS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| EP-2155668-A2 | CRYSTALLINE FORMS OF (R)-1-{2-Ý4'- (3-METHOXY-PROPANE-1- SULFONYL)-BIPHENYL-4-YL¨-ETHYL}-2-METHYL-PYRROLIDINE, AND COMPOSITIONS, AND METHODS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2009128907-A1 | PROCESSES USEFUL FOR THE SYNTHESIS OF (R)-1-{2-[4'-(3-METHOXYPROPANE-1-SULFONYL)-BIPHENYL-4-YL]-ETHYL}-2-METHYL-PYRROLIDINE | ARENA PHARMACEUTICALS, INC. (US) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009128907-A1 | PROCESSES USEFUL FOR THE SYNTHESIS OF (R)-1-{2-[4'-(3-METHOXYPROPANE-1-SULFONYL)-BIPHENYL-4-YL]-ETHYL}-2-METHYL-PYRROLIDINE | ARENA PHARMACEUTICALS, INC. (US) | 2009-10-22 | — | — | WO | disclosed |
| WO-2008153958-A2 | CRYSTALLINE FORMS OF (R)-1-{2-[4'- (3-METHOXY-PROPANE-1- SULFONYL)-BIPHENYL-4-YL]-ETHYL}-2-METHYL-PYRROLIDINE, AND COMPOSITIONS, AND METHODS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110040105-A1 | PROCESSES USEFUL FOR THE SYNTHESIS OF (R)-1--2-METHYL-PYRROLIDINE | DHPS, MRM1, ALDH18A1 | KCNH2 2327/4885HRH3 2097/4885CA2 4398/4885 |
| US-20100292288-A1 | CRYSTALLINE FORMS OF (R)-1-{2-[4`- (3-METHOXY-PROPANE-1- SULFONYL)-BIPHENYL-4-YL]-ETHYL}-2-METHYL-PYRROLIDINE, AND COMPOSITIONS, AND METHODS RELATED THERETO | HRH3, HRH4, HTR1D | KCNH2 1455/4885HRH3 1/4885CA2 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.